Plus   Neg

Jazz Pharmaceuticals (JAZZ) Is Climbing On Q4 Results

Jazz Pharmaceuticals (JAZZ) reported fourth quarter adjusted net income of $1.17 per share after the close Monday, compared to $0.63 per share in the previous year. The consensus estimate was for EPS of $1.09. The stock is now up 0.97 on 20K shares.

Jazz Pharmaceuticals traded in a range throughout Monday's session and closed down by 0.26 at $50.55. The stock pulled back from the upper end of over a month and a half long range, at the highs of the year.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Follow RTT